

Press Release - 6 July 2021

Palex, backed by Ergon Capital, acquires Biología y Técnica de la Radiación, S.L.

Barcelona (Spain) - Palex, the leading distributor of high value-added MedTech equipment and solutions in Spain and Portugal, announced today the acquisition of Biología y Técnica de la Radiación, S.L. (“Bioterra” or the “Company”). With such acquisition, Palex further strengthens its range of Oncology solutions and creates a new business division around radiation therapy.

Headquartered in Madrid (Spain) and founded in 2002, Bioterra provides innovative radiation therapy solutions to treat patients with cancer, including magnetic resonance imaging and proton therapy. The Company’s wide portfolio consists of leading and renowned OEM brands with the most advanced solutions. Bioterra counts with a dedicated salesforce and a technical service with nationwide presence.

Xavier Carbonell, CEO of Palex, commented on the transaction: *“We remain absolutely focused on supporting healthcare professionals and, as such, we strive to tailor our services and solutions to tackle the specific challenges within each therapeutic area. The acquisition of Bioterra fits perfectly within such spirit and Palex’s long-term strategy”.*

- END OF PRESS RELEASE -

For more information, please contact:

Ergon
John Mansvelt
+32 (2) 213 60 90
jm@ergoncapital.com

About Palex

Palex, founded in 1955 by the Knuth family, is a company focused on the marketing, sales and distribution of high value-added MedTech equipment and solutions in the Spanish and Portuguese markets. The Company has a strong reputation for innovation, quality and service and offers a wide product portfolio (+130,000 references) from world-leading manufacturers (+650 partnerships) and own products across numerous therapeutic areas. Palex counts with ~550 employees and is headquartered in Sant Cugat del Vallés (Barcelona, Spain).

For more information on Palex visit palexmedical.com.

About Bioterra

Founded in 2002 by Ms. Marisa Ogando, Bioterra provides innovative radiation therapy reagents and equipment from third-party leading OEMs to treat patients with cancer, including magnetic resonance imaging or proton therapy solutions. Bioterra is headquartered in Madrid (Spain).

For more information on Bioterra visit bioterra.net.

About Ergon

Ergon is a mid-market investment company with over €1.5 billion of assets under management from select European institutional investors and families. Ergon is a disciplined and discreet value investor, which provides “patient and friendly capital” to entrepreneurs and managers, who need capital, industrial or technological solutions to accelerate the development of their companies. Ergon makes equity investments in leading companies with a sustainable competitive position in attractive niche markets located in the Benelux, France, Germany, Iberia and Italy. Ergon is advised by Ergon Capital Advisors which has offices in Brussels, Paris, Munich, Madrid and Milan. Since its inception in 2005, over successive investment programs, Ergon has raised over €2.5 billion, invested in 30 companies (of which 9 in the Benelux, 9 in Italy, 4 in France, 5 in Germany and 3 in Spain) and completed 71 add-on acquisitions for a total aggregate transaction value of over €5.0 billion. Ergon’s current portfolio consists of 16 companies across its target sectors.

For more information on Ergon visit ergoncapital.com.